

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 February 2002 (28.02.2002)


PCT

(10) International Publication Number
WO 02/15951 A2

- (51) International Patent Classification⁷: **A61L 27/34**, 27/50
- (74) Agents: **STIFFLER, Lori** et al.; Baker Botts L.L.P., 910 Louisiana, Houston, TX 77002 (US).
- (21) International Application Number: PCT/US01/25880
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 20 August 2001 (20.08.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/226,897 23 August 2000 (23.08.2000) US
60/238,469 10 October 2000 (10.10.2000) US
09/933,256 20 August 2001 (20.08.2001) US
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant: **THORATEC CORPORATION** [US/US]; 6035 Stoneridge Drive, Pleasanton, CA 94588 (US).
- (72) Inventors: **JAYARAMAN, Ramesh, B.**; 1941 Briscoe Terrace, Fremont, CA 94539 (US). **CHRISTOFOROU, Christofer, T.**; 4240 Katie Lane, Pleasanton, CA 94588 (US).
- Published:**
— *without international search report and to be republished upon receipt of that report*

[Continued on next page]

(54) Title: COATED VASCULAR GRAFTS AND METHODS OF USE



(57) Abstract: A vascular graft, such as an AAA stent graft, includes a core zone of PET fabric with a non-porous coating comprising a polyurethane, such as Thoralon[®], disposed on at least one surface. The coating provides a barrier to prevent short and long term leakage of fluids through the pores of the PET fabric core zone. A method for sealing the pores of a porous PET graft includes the step of coating at least one surface of said graft with at least one polyurethane, or mixtures and combinations thereof. Preferably, the coating is Thoralon[®]. A method for making a vascular prosthesis includes the steps of providing a core zone of with at least one polyurethane, or mixtures and combinations thereof, such as Thoralon[®]. Finally, a method of repairing or treating a defective vessel includes the step of reinforcing or replacing the defective vessel with a graft according to the invention.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

COATED VASCULAR GRAFTS AND METHODS OF USE

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Patent
5 Application No. 60/226,897 entitled "Coated Vascular Grafts," filed August 23, 2000,
and U.S. Provisional Patent Application No. 60/238,469 entitled "Coated Vascular
Grafts," filed October 10, 2000.

BACKGROUND OF THE INVENTION

1. Field of the Invention

10 The present invention relates generally to vascular grafts. More
particularly, the present invention relates to woven or porous PET (polyethylene
terephthalate) grafts having unique polyurethane coatings to improve resistance to
permeability, useful in applications such as endolumenal repair of abdominal aortic
aneurysm.

15 2. Description of Related Art

Abdominal aortic aneurysm (AAA) is a leading cause of death in the
United States, causing an estimated 15,000 mortalities each year. An abdominal aortic
aneurysm is a bulge in the wall of the artery, usually a sequela of arteriosclerosis or the
buildup of plaque on the inside of the artery. If untreated, the aneurysm may rupture,
20 causing death.

One approach for the treatment of AAA involves invasive abdominal
surgery. The abdomen is opened and the aneurysm is identified. The aorta is opened
and a surgical graft is inserted into the aorta and sewn in place. The aorta is then closed
over the graft. More recently, stent grafts have been used in less-invasive procedures.
25 Stent grafts include a graft layer inside or outside a stent structure. The stent graft
provides a graft layer to reestablish a flow lumen through the aneurysm and a stent
structure to support the graft and to resist occlusion or stenosis. Stent grafts may be
inserted via incisions in the groin and deployed at the aneurysm site using a delivery
catheter. Once in place, the stent graft expands within the aorta, providing a path for
30 blood flow and reinforcing the weakened vessel. Examples of stent grafts are described

in U.S. Patent No. 6,015,431 to Thornton, et al. and published PCT International Application WO 98/27895.

A variety of materials have been used for vascular repair including PET (woven and knitted), Teflon®, bovine vessels, cryopreserved vessels of human or animal origin and others. Whether a traditional or stent graft, because of the size of the vessel being reinforced and the pressures within the vessel, AAA grafts must be made of strong and compliant textiles. Dacron®, or the more generic name, polyethylene terephthalate (PET), is an accepted and commonly used material for vascular repair, particularly for large diameter vascular grafts (>6 mm in diameter).

PET grafts are made in a similar fashion to most textiles. Fibers are woven or knitted into a specific geometry and structure. The result is a very strong "fabric" but one which is porous. Because integrity against leakage of the graft is important, such vascular grafts are often preclotted to prevent leaking. Alternately, graft pores have been sealed with collagen and other materials. However, although collagen and other coatings may provide sealing to prevent initial blood losses, known coatings have not proven adequate for more long term needs (>1-3 months) or cases where fluid (e.g., serum or water) permeability is important. The permeability of grafts is a particular problem in PET grafts for endolumenal AAA repair. Because of the porous nature and insufficiency of currently available coatings, over time seepage develops between the PET grafts and the aorta. In the case of AAA, permeability of the graft to any fluid can lead to worsening of the aneurysm.

SUMMARY OF THE INVENTION

Therefore, a need has arisen for grafts that provide the strength and compliance of woven PET grafts, while at the same time providing necessary short and long term resistance against leakage through the pores of the fabric. The present invention overcomes the problem of leakage through the pores seen with known large bore PET grafts.

The present invention is directed to grafts, such as stent grafts, made of fabrics coated with unique polyurethanes, such as Thoralon®, which provide a compliant, strong and impermeable barrier. Grafts according to the invention are particularly useful for the repair of vascular defects in large vessels, such as AAA. However, grafts coated according to the invention are not limited to AAA repair, and

may be used in a variety of applications, including vascular grafts (including endolumenal stent grafts) and vascular patches for any area of the body. Grafts according to the present invention provide good and physiologic biocompatibility, biostability, compliance, and strength.

5 In one embodiment of the invention, a vascular graft, such as an AAA stent graft, comprises a core zone or layer comprising a PET fabric. The core zone has a first surface and a second surface opposing the first surface. A non-porous or pore-free coating is disposed on at least the first surface. The coating comprises at least one polyurethane. Preferably the polyurethane is a polyurethane urea, and, most preferably,
10 is Thoralon®. The coating provides a barrier to prevent fluids from leaking through the pores of the PET fabric core zone. The core zone is preferably configured for use in a vessel having an internal diameter of more than 2 mm, and, more preferably, is configured for use in an abdominal aorta having an internal diameter of more than 6 mm.

15 Another embodiment of the invention provides a method for sealing the pores of a porous PET graft comprising the step of coating at least one surface of the graft with a polymer composition to produce a pore-free coat on the surface. The graft is preferably configured for use in a vessel having an internal diameter of more than 2 mm and, more preferably, is configured for use in an abdominal aorta having an
20 internal diameter of more than 6 mm. The polymer composition comprises at least one polyurethane. The polyurethanes are segmented and comprise a soft segment and a hard segment. Preferably, the polymer composition is Thoralon®.

 Methods for forming a vascular graft are also provided. For example, another embodiment of the invention provides a method for making a vascular
25 prosthesis comprising the steps of providing a core zone or layer comprising a PET fabric, the core zone having a first surface and a second surface opposing the first surface; and coating at least the first surface of the core zone with a polymer composition to produce a pore-free coat on the surface. As with the previous embodiment, the polymer composition comprises at least one polyurethane and, most
30 preferably, is Thoralon®. The core zone is preferably configured for use in a vessel having an internal diameter of more than 2 mm. Preferably, the vascular graft is an

AAA graft and the core zone is configured for use in an abdominal aorta having an internal diameter of more than 6 mm.

Another embodiment of the invention is directed to a method of repairing or treating a defective vessel in an individual, such as a vessel having an
5 internal diameter of more than 2 mm, comprising reinforcing or replacing the defective vessel with a graft according to the invention.

Other objects, features, and advantages will be apparent to those skilled in the art in view of the following description of the preferred embodiments and the accompanying drawings.

10 BRIEF DESCRIPTION OF THE DRAWINGS

The present invention may be more readily understood with reference to the following drawing in which:

Figure 1 is a cross-sectional view of the layered structure of a coated stent graft according to the invention.

15 DESCRIPTION OF PREFERRED EMBODIMENTS

The present invention is directed to vascular grafts made of porous fabrics, such as PET, coated with Thoralon® or other suitable polyurethanes, to prevent leakage of fluid through the pores of the graft. Specifically, the present invention uses blood-compatible polyurethanes, such as Thoralon®, as coatings for the blood-
20 contacting textiles. Coated textiles according to the invention have improved impermeability (*i.e.*, are less prone to allow leakage of fluids, such as serum or water, through the body of the graft, both long and short term). The present invention solves the problem of seepage between the graft and aorta through the pores of the fabric occurring with currently available coated PET grafts. The coatings of the invention
25 may be used to coat other grafts, including, but not limited to, ePTFE (expanded polytetrafluoroethylene) grafts.

Because polyurethanes have very low water permeability, they can effectively seal a textile. Furthermore, polyurethanes, such as Thoralon®, possess a number of desirable properties such as biostability, compliance, biocompatibility, blood
30 compatibility and strength, which are important in many vascular applications. As such, coated textiles according to the invention provide improved blood compatibility, as well as strong and compliant reinforcement or replacement of the diseased area.

Accordingly, grafts coated according to the invention may be used in a variety of applications, including vascular grafts, stent grafts and vascular patches. Grafts according to the invention are particularly useful in the repair of AAA.

Grafts according to the invention provide a number of advantages. By
5 using a polymer, preferably a polyether urethane urea such as Thoralon®, to seal the pores of a woven fabric graft, a blood compatible prosthesis is provided. Graft coatings need to be blood compatible because they come into contact with blood. In addition, the coatings of the invention adhere to the graft, seal the pore openings, and maintain their mechanical function (*e.g.*, prevent seepage between the graft and artery) *in vivo*
10 for a period of years.

The coatings of the invention can perform the necessary sealing function at low thicknesses. Ideally, the profile of a graft must be thin to allow for the smallest possible endolumenal intervention. Thoralon® has been successfully applied as thinly as 4-5 microns. Depending on the size of the pore which needs to be sealed, even
15 thinner applications may be achieved.

In view of this, the coatings of the invention are particularly useful for coating flat, uncrimped tubes of PET, to create a graft having a very thin profile, which is highly beneficial in endovascular applications.

By using the coatings of the invention, the pores of a porous PET stent
20 graft have been effectively sealed, thereby reducing the permeability of a PET graft without altering the profile of the material by more than 50%. In addition to PET, grafts or patches made of other porous materials, such as ePTFE, may be effectively sealed.

Coatings according to the invention, such as Thoralon® coatings, not
25 only provide a non-thrombogenic and an improved blood-compatible lumen surface, but may also be used as a drug delivery vehicle (*e.g.*, deliver a pharmacological agent) and as a surface-modifying coating to alter mechanical properties such as compliance and wear resistance. Also, Thoralon® may be applied as a foam to promote cell adhesion (such as endothelial cells) to form a neointima in all vascular graft
30 applications.

A number of different coating materials may be applied to the porous graft fabric according to the invention to seal the pores and reduce permeability. These

include polyurethane ureas, other polyurethanes, and mixtures of them. As used herein, the term "polyurethane" includes polyurethane urea as well as other polyurethanes. Coatings may also comprise the other materials as described below.

A preferred material for use as a coating according to the invention is
5 Thoralon®. Thoralon® (Thoratec Corporation, Pleasanton, CA) is a polyetherurethane urea blended with a siloxane containing surface modifying additive, and has been demonstrated to provide effective sealing of textile grafts. Thoralon® can be obtained from Thoratec Corporation, Pleasanton, CA. Specifically, Thoralon® is a mixture of base polymer BPS-215 and an additive SMA-300 in dimethylacetamide (DMAC)
10 solvent. The concentration of additive is preferably in the range of 0.5% to 5% by weight of the base polymer.

The BPS-215 component (Thoratec Corporation, Pleasanton, CA) used in Thoralon® is a segmented polyether urethane urea containing a soft segment and a hard segment. The soft segment is made of polytetramethylene oxide (PTMO) and the
15 hard segment is made of 4,4'-diphenylmethane diisocyanate (MDI) and ethylene diamine (ED).

The SMA-300 component is a polyurethane comprising polydimethylsiloxane as a soft segment and MDI and 1,4 butanediol as a hard segment. A process for synthesizing SMA-300 is described, for example, in U.S. Patent No.
20 4,861,830 to Ward, Jr., at Column 14, Lines 17-41, and U.S. Patent No. 4,675,361 to Ward, Jr., at Column 14, Lines 13-37, incorporated herein by reference.

Thoralon® is FDA approved for use in certain vascular applications and has been shown to be safe and effective in a variety of critical applications because it offers thromboresistance, high tensile strength, and superb flex life. Thoralon® has
25 been shown to be biostable and useful *in vivo* in long term blood contacting applications requiring biostability and leak resistance for periods exceeding one year or more. Thoralon® has been shown to reduce platelet deposition and binding on blood contacting surfaces of extracorporeal circuits in patients undergoing cardiopulmonary bypass. Because of its flexibility, Thoralon® is particularly beneficial in larger vessels,
30 such as the abdominal aorta, where elasticity and compliance is essential.

Thorlon®'s lower water absorption contributes to enhanced *in vivo* stability, while its lower critical surface tension and longer Lee White Clotting Times demonstrate improved blood compatibility and thromboresistance (Table 1).

5 **Table 1 - Physical Properties of Thorlon® in Comparison to Biomer**

Physical Properties	Biomer	Thorlon®
Water Absorption	4.1% wt gain	1.8% wt. gain
Critical Surface Tension	27.8 dynes/cm	19.8 dynes/cm
Lee White Clotting Times	29.1 minutes	37 minutes

In addition to Thorlon®, other polyurethane ureas may be used to coat the fabric component of the graft. For example, BPS-215 with a capping ratio
 10 (MDI/PTMO mole ratio) ranging from about 1.0 to about 2.5 may be used. Such polyurethane ureas preferably comprise a soft segment, and a hard segment comprising a diisocyanate and diamine. For example, polyurethane ureas with soft segments such as polyethylene oxide, polypropylene oxide, polycarbonate, polyolefin, polysiloxane (*e.g.*, polydimethylsiloxane), and other polyether soft segments made from higher
 15 homologous series of diols may be used. Mixtures of any of the soft segments may also be used. The soft segments may also have either alcohol or amine end groups. The molecular weight of the soft segments may vary from about 500 to about 5,000 g/mole, and preferably is about 2,000 g/mole.

The diisocyanate used as a component of the hard segment may be
 20 represented by the formula OCN-R-NCO. R may be aliphatic, aromatic, cycloaliphatic or aromatic-aliphatic. Representative diisocyanates useful in the invention include, but are not limited to, tetramethylene diisocyanate, hexamethylene diisocyanate, trimethyhexamethylene diisocyanate, tetramethylxylylene diisocyanate, 4,4'-decyclohexylmethane diisocyanate, dimer acid diisocyanate, isophorone diisocyanate,
 25 metaxylene diisocyanate, diethylbenzene diisocyanate, decamethylene 1,10 diisocyanate, cyclohexylene 1,2-diisocyanate, 2,4-toluene diisocyanate, 2,6-toluene diisocyanate, xylene diisocyanate, m-phenylene diisocyanate, hexahydrotolylene diisocyanate (and isomers), naphthylene-1,5-diisocyanate, 1-methoxyphenyl 2,4-diisocyanate, 4,4'-biphenylene diisocyanate, 3,3-dimethoxy-4,4'-biphenyl diisocyanate
 30 and mixtures thereof.

Suitable diamines useful as a component of the hard segment include aliphatic, aromatic and aliphatic-aromatic amines. For example, useful diamines include, but are not limited to, ethylene diamine, propane diamines, butanediamines, hexanediamines, pentane diamines, heptane diamines, octane diamines, m-xylylene diamine, 1,4-cyclohexane diamine, 2-methypentamethylene diamine, 4,4'-methylene dianiline, and mixtures thereof. The amines may also contain nitrogen, oxygen or halogen.

In addition to polyurethane ureas, other polyurethanes (preferably having a chain extended with diols) may be used to coat the fabric of the graft. Polyurethanes modified with cationic, anionic and aliphatic side chains may also be used (*see, e.g.*, U.S. Patent No. 5,017,664 to Grasel, at Column 1, Lines 57-63, and Column 8, line 60 - Column 11, Line 27). Polyurethanes may have to be dissolved in solvents such as dimethyl formamide, tetrahydrofuran, dimethylacetamide, etc., or mixtures thereof.

The soft segments of these polyurethanes may be comprised of any of the soft segments mentioned above (including, but not limited to, polytetramethylene oxide, polyethylene oxide, polypropylene oxide, polycarbonate, polyolefin, polysiloxane (*e.g.*, polydimethylsiloxane), other polyether soft segments made from higher homologous series of diols, and mixtures of these soft segments. The soft segments may have amine or alcohol end groups).

The hard segment may be comprised of any of the diisocyanates listed above (including, but not limited to, 4,4'-diphenylmethane diisocyanate, tetramethylene diisocyanate, hexamethylene diisocyanate, trimethyhexamethylene diisocyanate, tetramethylxylylene diisocyanate, 4,4'-decyclohexylmethane diisocyanate, dimer acid diisocyanate, isophorone diisocyanate, metaxylene diisocyanate, diethylbenzene diisocyanate, decamethylene 1,10 diisocyanate, cyclohexylene 1,2-diisocyanate, 2,4-toluene diisocyanate, 2,6-toluene diisocyanate, xylene diisocyanate, m-phenylene diisocyanate, hexahydrotolylene diisocyanate (and isomers), naphthylene-1,5-diisocyanate, 1-methoxyphenyl 2,4-diisocyanate, 4,4'-biphenylene diisocyanate, 3,3-dimethoxy-4,4'-biphenyl diisocyanate and mixtures thereof).

The hard segment may be comprised of polyols. Polyols may be aliphatic, aromatic, aromatic-aliphatic or cycloaliphatic. Preferred polyols include, but

are not limited to, ethylene glycol, diethylene glycol, triethylene glycol, 1,4-butanediol, neopentyl alcohol, 1,6-hexanediol, 1,8-octanediol, propylene glycols, 2,3-butylene glycol, dipropylene glycol, dibutylene glycol, glycerol, and mixtures thereof.

In addition, the polyurethanes may also be end-capped with surface
5 active end groups, such as, for example, polydimethylsiloxane, fluoropolymers, polyolefin, polyethylene oxide, or other suitable groups, including, but not limited to, those described in U.S. Patent No. 5,589,563 to Ward Jr. et al. (*see, e.g.*, Examples 2, 3, 5 and 8, at Column 28, Line 60 - Column 31, Line 22, of U.S. Patent No. 5,589,563, incorporated herein by reference).

10 In addition to the foregoing polymers, other useful materials for coating porous grafts include silicone rubber, polyisobutylene copolymer, polyolefin, polyester, polyamide, amorphous polyamide and mixtures and combinations of the above. As will be clear to those of skill in the art, suitable solvents are used to make solutions of these materials. For example, silicone rubber may be dissolved in heptanes and toluene
15 may be used for polyolefins.

Figure 1 depicts a preferred embodiment of an AAA stent graft according to the invention. Referring to Figure 1, AAA stent graft 10 comprises a cylindrical PET fabric core zone 12. A polyurethane coating 14 is disposed on the inner diameter 18 and outer diameter 20 of zone 12. As can be seen in Figure 1, the
20 polyurethane matrix preferably permeates or infiltrates the spaces between the woven fibers of fabric core zone 12. Reinforcing layer 16 is disposed on the outside of core zone 12 and coating 14. Reinforcing layer 16 preferably comprises a plurality of stent wires made of stainless steel, nickel titanium alloy, or another suitable material.

Accordingly, one embodiment of the invention is directed to a vascular
25 graft comprising a core zone or layer made of a PET fabric. The core zone is preferably configured or shaped for use in a vessel or for repair of a vessel having an internal diameter of more than 2 mm. More preferably, the vessel has an internal diameter of more than 3 mm, and, most preferably, more than 6 mm. The core zone has a first surface and a second surface opposing the first surface. A first non-porous
30 coating is disposed on the first surface. This coating comprises at least one polyurethane, and preferably comprises a polyurethane urea. Preferably, the core zone comprises woven or knitted PET.

The coated first surface is preferably the blood interface surface of the graft. Alternately, the coated first surface may be the artery/tissue interface surface. In other words, the coating may be applied to either surface of the graft.

A second coating may be applied to the opposite surface of the graft.

5 Alternately, a first coating applied to one surface may permeate through and form a cover or second coating on the opposing surface of the graft. For example, polyurethane applied to the first surface to form the first coating may penetrate the core zone and form the second coating on the second surface.

Although the present invention provides for a biocompatible, leak-

10 resistant graft using a single coating material, if desired, in an alternate embodiment, one surface may be coated with one type of material, and the opposite or same surface coated with another type of material.

The core zone may have any desired shape, such as a cylinder, a bifurcated/Y-shaped cylinder, or a substantially flat sheet for patches.

15 In a preferred embodiment, at least a portion of the core zone has a substantially cylindrical shape and is a graft having an internal diameter of greater than 2 mm, and, more preferably, greater than 3 mm. Even more preferably, the graft is a large bore graft, in which the internal diameter is greater than 6 mm and the outer diameter is greater than 6.1 mm. For example, the external diameter may be designed

20 or configured to fit in a large bore vessel, such as an abdominal aorta of an adult human. Alternately, it may be designed to fit within other vessels, such as a human femoral artery or carotid artery.

The first surface is preferably disposed on the inner surface of the cylindrical core zone, *i.e.*, the first coating is on the inner diameter of the cylinder.

25 Alternately, the first surface may be disposed on the outer surface of the cylindrical core zone, *i.e.*, the first coating may be on the outer diameter of the cylindrical core zone. If desired, the graft may have a coating on both surfaces, *i.e.*, both the first and second surfaces. The coatings may be applied separately to each side or, as noted, when the first coating is applied to one surface, it may permeate through and form a

30 second coating on the opposing surface of the graft.

The graft may be used in a variety of applications, including as a vascular graft, as a stent graft or as a vascular patch. The graft is particularly useful for

large bore vessels having an internal diameter of 6 mm or more. In a preferred embodiment, the graft comprises an AAA stent graft such as an AneuRx™ graft, supplied by Medtronic, Inc., Minneapolis, MN. Other grafts which may be used include, but are not limited to, Ancure® AAA grafts manufactured by Guidant Corporation (headquartered in Indianapolis, IN; with facilities in Menlo Park, CA). In this embodiment, the stent graft may further comprise a more rigid component, such as stent wire or other suitable component to provide structural support to the stent graft. Preferably, the reinforcement is made of stainless steel or nickel-titanium alloy.

The coating on the PET fabric core may be comprised of any of the various materials described. For example, the coating may comprise a polyether urethane urea blended with a siloxane containing a surface modifying additive. The coating may comprise a polyether urethane urea, which has a soft segment comprising polytetramethylene oxide (PTMO) and hard segment comprising 4,4'-diphenylmethane diisocyanate (MDI) and ethylene diamine.

In a preferred embodiment, the coating comprises Thoralon®. However, the coating may comprise one or more polyurethanes, or mixtures and combinations thereof. Preferably, the polyurethanes each comprise a soft segment and a hard segment. As discussed above, the soft segment may comprise one or more compounds selected from the group consisting of polytetramethylene oxide, polyethylene oxide, polypropylene oxide, polycarbonate, polyolefin, polysiloxane (*e.g.*, polydimethylsiloxane), polyether soft segments made from higher homologous series of diols, and mixtures and combinations thereof. The soft segments may also have either alcohol or amine end groups.

The hard segment is comprised of an isocyanate (preferably a diisocyanate) and an amine (preferably a diamine) or a polyol. Alternately, the hard segment may comprise an isocyanate and both an amine and a polyol. The isocyanate component of the hard segment may comprise one or more compounds selected from the group consisting of 4,4'-diphenylmethane diisocyanate (MDI), tetramethylene diisocyanate, hexamethylene diisocyanate, trimethylhexamethylene diisocyanate, tetramethylxylylene diisocyanate, 4,4'-decyclohexylmethane diisocyanate, dimer acid diisocyanate, isophorone diisocyanate, metaxylene diisocyanate, diethylbenzene diisocyanate, decamethylene 1,10 diisocyanate, cyclohexylene 1,2-diisocyanate, 2,4-

toluene diisocyanate, 2,6-toluene diisocyanate, xylene diisocyanate, m-phenylene diisocyanate, hexahydrotolylene diisocyanate (and isomers), naphthylene-1,5-diisocyanate, 1-methoxyphenyl 2,4-diisocyanate, 4,4'-biphenylene diisocyanate, 3,3-dimethoxy-4,4'-biphenyl diisocyanate, and mixtures and combinations thereof. The
5 amine component of the hard segment may comprise one or more compounds selected from the group consisting of ethylene diamine, propane diamines, butanediamines, hexanediamines, pentane diamines, heptane diamines, octane diamines, m-xylylene diamine, 1,4-cyclohexane diamine, 2-methypentamethylene diamine, 4,4'-methylene dianiline, alkanol amines and diamines, and mixtures and combinations thereof. The
10 polyol component of the hard segment may comprise one or more compounds selected from the group consisting of ethylene glycol, diethylene glycol, triethylene glycol, 1,4-butanediol, neopentyl alcohol, 1,6-hexanediol, 1,8-octanediol, propylene glycols, 2,3-butylene glycol, dipropylene glycol, dibutylene glycol, glycerol, and mixtures and combinations thereof.

15 Another embodiment of the invention is directed to a method for sealing the pores of a porous PET graft comprising the step of coating at least one surface of the graft with a polymer composition to produce a pore-free coat on the surface, the polymer composition comprising at least one polyurethane, or mixtures and combinations of polyurethanes, as described herein. The graft is preferably configured
20 for use in a vessel or to repair a vessel having an internal diameter of more than 2 mm. More preferably, the vessel has an internal diameter of more than 3 mm, and, most preferably, more than 6 mm. Preferably, the graft comprises an AAA stent graft and the polymer composition comprises Thoralon®.

The invention is also directed to methods of making PET grafts having
25 reduced permeability. In making such grafts, adhesion of the polyurethane to the textile is a critical parameter. To enhance adhesion, the textile may be pretreated by washing the textile in methylene chloride, acetone, or another suitable agent. Alternately, additives to the polyurethane may be used to promote effective bonding. Examples include, but are not limited to, Thoralon® with and without siloxane additive
30 (SMA).

The coating can be applied in a variety of ways, including but not limited to, spraying, dipping, applying with rollers or brushes, or casting. These

processes can be applied on a textile sheet, graft or final product construct (*e.g.*, stented graft) to improve the functional performance of the product by reducing permeability. As noted, coating material applied to one side may permeate through and form a cover or coating on both surfaces of the graft.

5 In a preferred method, the coating applied to the graft is formed from a solution of polyurethane that readily penetrates the graft. By using such solutions, no pressure is needed to get the coating to permeate into the pores of the graft.

 As noted, the actual application of the different coatings of the invention may be accomplished in a number of ways. For example, the polymer composition
10 may be applied using a brush, followed by heating the coated part in an oven while rotating the coated part to drive off the solvent. One or more coating layers may be applied to attain desirable thickness.

 Alternately, the polymer composition may be sprayed onto the fabric core using a spray nozzle and the coating may be dried. Alternately, the core may be
15 dip coated. Useful methods for dip coating and spray coating are described, for example, in U.S. Patent No. 5,104,400 to Berguer et al.

 If desired, the polymers may also be reacted in place. For example, two-component polyurethane or silicone rubber may be used. The coating may also be obtained by coating a suitable monomer, by itself or in a solvent on the fabric and
20 polymerizing by thermal energy (heat) or high-energy light sources such as UV.

 Accordingly, another embodiment is directed to a method for making a vascular prosthesis comprising providing a core zone or layer comprising a porous PET fabric, the core zone having a first surface and a second surface opposing the first surface; and coating at least the first surface of the core zone with a polymer
25 composition (*e.g.*, in slurry or solution form) to produce a first pore-free coat on the first surface. The core zone is preferably configured for use in a vessel or to repair a vessel having an internal diameter of more than 2 mm. More preferably, the vessel has an internal diameter of more than 3 mm, and, most preferably, more than 6 mm. The polymer composition may penetrate the core zone to produce a second coat on the
30 second surface. Alternately, the second surface may be separately coated with the polymer composition. The polymer composition preferably comprises at least one polyurethane, or mixtures and combinations of polyurethanes, as described herein.

The step of coating may be accomplished by spraying at least one layer of the polymer composition on the first surface of the core zone and allowing the layer to dry. These steps may be repeated one or more times until the desired thickness is obtained. Alternately, the step of coating may comprise applying the polymer composition to the first surface with a brush or roller. In this embodiment, the method may further comprise heating the coated surface to drive off any solvent. Alternately, the step of coating may comprise dipping the core zone in a slurry of the polymer composition one or more times.

Regardless of the application process, drying of the coating is optimally accomplished at temperatures in a range of about 30°C to about 150°C, and most preferably, at a temperature about 60°C.

In another variation, the step of coating may comprise coating at least the first surface with a monomer and polymerizing the monomer to form the polymer composition by thermal energy or high energy light.

Optionally, the method may further comprise pretreating the core zone by washing in methylene chloride or another suitable agent. If desired, one or more additives may be added to the polymer composition to enhance bonding of the polymer composition to the core zone.

Another embodiment of the invention is directed to a method of repairing or treating a defective vessel in an individual, such as a vessel having an internal diameter of more than 2 mm, comprising reinforcing or replacing the defective vessel with a graft according to the invention. The individual may be any animal, and is preferably a mammal, such as a human. The defective vessel may be any vessel, and is preferably a large bore vessel, such as the abdominal aorta of a human.

The following examples are offered to illustrate embodiments of the invention, and should not be viewed as limiting the scope of the invention.

EXAMPLES

Example 1 - Water Permeability Test

In this example, the water permeability of uncoated graft fabric was compared to fabrics coated with Thoralon®. Testing was performed in accordance with Association of the Advancement of Medical Instrumentation, ANSI/AAMI VP20,

1994, with the exception of the diameter of the opening, as discussed below. The uncoated fabric tested was made of polyester, and more specifically, was fabric from an AAA graft (AneuRxTM polyester fabric graft, supplied by Medtronic, Inc., Minneapolis, MN). This same fabric was also coated with about a 12 micron layer of Thoralon® on both sides.

The samples were tested as follows. Approximately 1 cm² of fabric was cut and sandwiched between two acrylic plates containing a circular opening at the center measuring 0.1257 cm² in diameter. The plates were then connected to (sandwiched between) two acrylic tubes having the same radius inner diameter. One of the tubes was connected to a water column that provided a constant pressure of 100 ± 1 mm Hg. The water was allowed to flow through the fabric for 2 minutes, and the water passing through the fabric was collected. The collected quantity of water was determined. The results shown in Table 2 are an average of triplicate analysis and are reported in terms of cc/min/cm².

Table 2

<u>Material</u>	<u>Flow Rate (cc/min/cm²)</u>
uncoated fabric	240 ± 8
Thoralon® coated fabric	no flow

As can be seen from Table 2, there was no flow of water through the Thoralon® coated fabric, confirming that Thoralon® coatings can dramatically improve the water permeability of porous graft fabrics.

Although the invention has been described with respect to preferred embodiments, the foregoing description and examples are intended to be merely exemplary of the invention. The true scope and spirit of the invention is not intended to be limited by the foregoing description and examples, but instead is intended to be commensurate with the scope of the following claims. Variations and modifications on the elements of the claimed invention will be apparent to persons skilled in the art from a consideration of this specification or practice of the invention disclosed herein.

CLAIMS

What is claimed is:

1. A vascular graft comprising:
a core zone comprising a PET fabric, said core zone configured for use in a
5 vessel having an internal diameter of more than 2 mm, said core zone having a first
surface and a second surface opposing said first surface; and
a first non-porous coating disposed on at least said first surface, wherein said
first coating comprises at least one polyurethane.
2. The graft of claim 1 wherein said core zone comprises woven or knitted PET.
- 10 3. The graft of claim 1 wherein said first surface is a blood interface surface.
4. The graft of claim 1 wherein said first surface is an artery or tissue interface
surface.
5. The graft of claim 1 wherein at least a portion of said core zone has a
substantially cylindrical shape.
- 15 6. The graft of claim 5 wherein the core zone has an internal diameter of more
than 6 mm.
7. The graft of claim 5 wherein said first surface is disposed on the inner surface
of said cylindrical core zone.
8. The graft of claim 5 wherein said first surface is disposed on the outer surface
20 of said cylindrical core zone.
9. The graft of claim 1 wherein said graft further comprises a second coating
disposed on said second surface.
10. The graft of claim 9 wherein polyurethane applied to said first surface to form
said first coating penetrates said core zone and forms said second coating on said
25 second surface.
11. The graft of claim 1 wherein said graft comprises an AAA stent graft.
12. The graft of claim 1 wherein said graft is a vascular graft, a stent-graft or a
vascular patch.
13. The graft of claim 1 wherein the coating comprises a polyurethane urea.
- 30 14. The graft of claim 1 wherein the coating comprises a polyetherurethane urea
blended with a siloxane containing a surface modifying additive.
15. The graft of claim 1 wherein the coating comprises Thoralon®.

16. The graft of claim 1 wherein said at least one polyurethane comprises a soft segment and a hard segment.
17. The graft of claim 16 wherein the soft segment has a molecular weight of about 2,000 g/mole.
- 5 18. The graft of claim 16 wherein the soft segment comprises one or more compounds selected from the group consisting of polyethylene oxide, polypropylene oxide, polytetramethylene oxide, polycarbonate, polyolefin, polysiloxane, polyether soft segments made from higher homologous series of diols, and mixtures and combinations thereof.
- 10 19. The graft of claim 16 wherein the hard segment comprises one or more compounds selected from the group consisting of 4,4'-diphenylmethane diisocyanate, tetramethylene diisocyanate, hexamethylene diisocyanate, trimethyhexamethylene diisocyanate, tetramethylxylylene diisocyanate, 4,4'-decyclohexylmethane diisocyanate, dimer acid diisocyanate, isophorone diisocyanate, metaxylene diisocyanate, diethylbenzene diisocyanate, decamethylene 1,10 diisocyanate, cyclohexylene 1,2-diisocyanate, 2,4-toluene diisocyanate, 2,6-toluene diisocyanate, xylene diisocyanate, m-phenylene diisocyanate, hexahydrotolylene diisocyanate (and isomers), naphthylene-1,5-diisocyanate, 1-methoxyphenyl 2,4-diisocyanate, 4,4'-biphenylene diisocyanate, 3,3-dimethoxy-4,4'-biphenyl diisocyanate, ethylene diamine, propane diamines, butanediamines, hexanediamines, pentane diamines, heptane diamines, octane diamines, m-xylylene diamine, 1,4-cyclohexane diamine, 2-methypentamethylene diamine, 4,4'-methylene dianiline, alkanol amines and diamines, ethylene glycol, diethylene glycol, triethylene glycol, 1,4-butanediol, neopentyl alcohol, 1,6-hexanediol, 1,8-octanediol, propylene glycols, 2,3-butylene glycol, dipropylene glycol, dibutylene glycol, glycerol, and mixtures and combinations thereof.
- 15 20. The graft of claim 16 wherein said coating comprises a polyether urethane urea, and wherein said soft segment comprises polytetramethylene oxide (PTMO) and said hard segment comprises 4,4'-diphenylmethane diisocyanate (MDI) and ethylene diamine.
- 20 21. A method for sealing the pores of a porous PET graft comprising the step of:
coating at least one surface of said graft with a polymer composition to produce a pore-free coat on said surface, said polymer composition comprising at least one
- 25 30

polyurethane, said polyurethanes comprising a soft segment and a hard segment, said graft configured for use in a vessel having an internal diameter of more than 2 mm.

22. The method of claim 21 wherein said graft comprises an AAA stent graft.

23. The method of claim 21 wherein said polymer composition comprises
5 Thoralon®.

24. The method of claim 21 wherein said soft segment comprises one or more compounds selected from the group consisting of polyethylene oxide, polypropylene oxide, polytetramethylene oxide, polycarbonate, polyolefin, polysiloxane, polyether soft segments made from higher homologous series of diols, and mixtures and
10 combinations thereof.

25. The method of claim 21 wherein said hard segment comprises one or more compounds selected from the group consisting of 4,4'-diphenylmethane diisocyanate, tetramethylene diisocyanate, hexamethylene diisocyanate, trimethyhexamethylene diisocyanate, tetramethylxylylene diisocyanate, 4,4'-decyclohexylmethane
15 diisocyanate, dimer acid diisocyanate, isophorone diisocyanate, metaxylene diisocyanate, diethylbenzene diisocyanate, decamethylene 1,10 diisocyanate, cyclohexylene 1,2-diisocyanate, 2,4-toluene diisocyanate, 2,6-toluene diisocyanate, xylene diisocyanate, m-phenylene diisocyanate, hexahydrotolylene diisocyanate (and isomers), naphthylene-1,5-diisocyanate, 1-methoxyphenyl2,4-diisocyanate, 4,4'-
20 biphenylene diisocyanate, 3,3-dimethoxy-4,4'-biphenyl diisocyanate, ethylene diamine, propane diamines, butanediamines, hexanediamines, pentane diamines, heptane diamines, octane diamines, m-xylylene diamine, 1,4-cyclohexane diamine, 2-methylpentamethylene diamine, 4,4'-methylene dianiline, alkanol amines and diamines, ethylene glycol, diethylene glycol, triethylene glycol, 1,4-butanediol, neopentyl
25 alcohol, 1,6-hexanediol, 1,8-octanediol, propylene glycols, 2,3-butylene glycol, dipropylene glycol, dibutylene glycol, glycerol, and mixtures and combinations thereof.

26. A method for making a vascular prosthesis comprising:

providing a core zone comprising a PET fabric, said core zone configured for use in a vessel having an internal diameter of more than 2 mm, said core zone having a
30 first surface and a second surface opposing said first surface; and

coating at least the first surface of the core zone with a polymer composition to produce a first pore-free coat on said first surface, said polymer composition

comprising at least one polyurethane, said polyurethanes comprising a soft segment and a hard segment.

27. The method of claim 26 wherein the step of coating comprises:

5 spraying at least one layer of the polymer composition on the first surface of the core zone; and

allowing said layer to dry.

28. The method of claim 27 wherein said step of allowing said layer to dry comprises heating said layer to between about 30°C to about 150°C.

29. The method of claim 27 wherein said step of allowing said layer to dry
10 comprises heating said layer to about 60°C.

30. The method of claim 26 wherein the step of coating comprises applying said polymer composition to said first surface with a brush or roller.

31. The method of claim 30 further comprising heating the coated surface to drive off any solvent.

15 32. The method of claim 31 wherein said coated surface is heated to between about 30 °C to about 150°C.

33. The method of claim 31 wherein said coated surface is heated to about 60°C.

34. The method of claim 26 further comprising coating the second surface with said polymer composition.

20 35. The method of claim 26 wherein the step of coating comprises dipping the core zone in a slurry or solution of said polymer composition.

36. The method of claim 26 wherein the step of coating comprises coating at least the first surface with a monomer and polymerizing the monomer to form the polymer composition by thermal or high energy light.

25 37. The method of claim 26 wherein said graft comprises an AAA stent graft.

38. The method of claim 26 wherein said polymer composition comprises Thoralon®.

39. The method of claim 26 wherein said soft segment comprises one or more compounds selected from the group consisting of polyethylene oxide, polypropylene oxide, polytetramethylene oxide, polycarbonate, polyolefin, polysiloxane, polyether
30 soft segments made from higher homologous series of diols, and mixtures and combinations thereof.

40. The method of claim 26 wherein said hard segment comprises one or more compounds selected from the group consisting of 4,4'-diphenylmethane diisocyanate, tetramethylene diisocyanate, hexamethylene diisocyanate, trimethyhexamethylene diisocyanate, tetramethylxylylene diisocyanate, 4,4'-decyclohexylmethane
5 diisocyanate, dimer acid diisocyanate, isophorone diisocyanate, metaxylene diisocyanate, diethylbenzene diisocyanate, decamethylene 1,10 diisocyanate, cyclohexylene 1,2-diisocyanate, 2,4-toluene diisocyanate, 2,6-toluene diisocyanate, xylene diisocyanate, m-phenylene diisocyanate, hexahydrotolylene diisocyanate (and isomers), naphthylene-1,5-diisocyanate, 1-methoxyphenyl2,4-diisocyanate, 4,4'-
10 biphenylene diisocyanate, 3,3-dimethoxy-4,4'-biphenyl diisocyanate, ethylene diamine, propane diamines, butanediamines, hexanediamines, pentane diamines, heptane diamines, octane diamines, m-xylylene diamine, 1,4-cyclohexane diamine, 2-methylpentamethylene diamine, 4,4'-methylene dianiline, alkanol amines and diamines, ethylene glycol, diethylene glycol, triethylene glycol, 1,4-butanediol, neopentyl
15 alcohol, 1,6-hexanediol, 1,8-octanediol, propylene glycols, 2,3-butylene glycol, dipropylene glycol, dibutylene glycol, glycerol, and mixtures and combinations thereof.

41. The method of claim 26 further comprising pretreating the core zone by washing in methylene chloride.

42. The method of claim 26 wherein the polymer composition further comprises
20 one or more additives to enhance bonding of the polymer composition to the core zone.

43. The method of claim 26 wherein the step of coating further comprises allowing the polymer composition to penetrate the core zone to produce a second coat on said second surface.

44. The method of claim 26 wherein the polymer composition comprises a
25 polyurethane modified with a cationic, anionic or aliphatic side chain.

45. The method of claim 26 wherein the polymer composition comprises a heat or UV polymerizable polymer.

46. A method for repairing a defective vessel in an individual, said vessel having an internal diameter of more than 2 mm, comprising:

30 reinforcing or replacing said defective vessel with a vascular graft comprising a PET fabric core zone and a polyurethane coating disposed on at least one surface of said core zone.

- 47. The method of claim 46 wherein said individual is a mammal.
- 48. The method of claim 46 wherein said individual is a human.
- 49. The method of claim 46 wherein said defective vessel is an abdominal aorta.




Fig 1